Peptide GAM Immunoadsorption Therapy in Autoimmune Membranous Nephropathy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

12 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-11-30

Study Completion Date

2019-04-03

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Autoimmune Membranous Nephropathy is now understood to be a condition caused by the immune system although the exact mechanism is not completely known. This study aims to remove the offending part of the immune system using immunoadsorption to not only treat the disease but also use the opportunity to better understand the mechanism of disease. This will allow more targeted treatment in the future with less complications and side effects.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study With Imlifidase in Anti-GBM Disease

NCT05679401

Anti-Glomerular Basement Membrane Disease Anti-Glomerular Basement Membrane Antibody Disease Goodpasture Syndrome +1 more

ACTIVE_NOT_RECRUITING PHASE3

Trial to Assess Safety and Efficacy of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN)

NCT04145440

Glomerulonephritis, Membranous antiPLA2R Positive

COMPLETED PHASE1/PHASE2

A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease

NCT06500702

Focal Segmental Glomerulosclerosis Glomerulonephritis Minimal Lesion

RECRUITING PHASE2

An Open-Label, Long-term Study of GFB-887 in Patients With Glomerular Kidney Diseases

NCT04950114

Kidney Diseases Glomerulosclerosis Focal Segmental Nephrosis +4 more

TERMINATED PHASE2

The Effect of Nefecon® in Patients With Primary IgA Nephropathy at Risk of Developing End-stage Renal Disease

NCT01738035

Primary IgA Nephropathy

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Membranous nephropathy (MN) is among the most common causes of nephrotic syndrome in adults worldwide. The majority of patients will remain stable with either complete remission or partial remission but approximately 20% will progress slowly to end stage renal disease necessitating the need for renal replacement therapy (RRT).

Current standard therapy for primary (or autoimmune) membranous nephropathy is a regime of rotating high dose steroids and immunosuppression was first described in the mid-nineties and has been the mainstay of treatment since but comes with a high side effect burden.

Idiopathic membranous nephropathy is now understood to be an autoimmune disease characterised by the presence of IgG autoantibodies to M-Type Phospholipase A2 Receptor (anti-PLA2R). Immunoadsorption is a method of removing specific circulating immunoglobulins and has been shown to remove over 80% of circulating IgG with a single session immunoadsorption of 2.5 plasma volumes, with albumin and antithrombin III almost unaffected. With multiple sessions this can rise to over 98%.

Immunoadsorption therapy has been in use for a number of years and this study will use Peptide GAM Immunoadsorption therapy developed by Fresenius Healthcare. This uses two systems, the Art Universal and ADAsorb. The Art Universal became commercially available in 2005 and the ADAsorb in 2002.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Autoimmune Membranous Nephropathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Immunoadsorption therapy

Peptide GAM immunoadsorption therapy

Group Type EXPERIMENTAL

Immunoadsorption

Intervention Type DEVICE

Fresenius Globaffin

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Immunoadsorption

Fresenius Globaffin

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Biopsy confirmed Primary Membranous Nephropathy within the last 3 years
* Active disease despite 6 months of supportive care including ACEi or ARB (Active disease defined as uPCR \> 300mg/mmol or 24 hour urinary protein \>3.5g/1.73m2)
* Disease severity that in the physicians view warrants treatment prior to completion of 6 months supportive care
* Anti-PLA2R titre \> 170 u/ml
* Haemophilus and Pneumococcal vaccinations up to date
* Above the age of 18
* Able to provide informed consent

Exclusion Criteria

* Evidence of causes of secondary membranous nephropathy
* eGFR \< 20ml/min
* Treatment with steroids or immunosuppression (including but not limited to cyclophosphamide, MMF or azathioprine) and Biologics (including but limited to Rituximab or belimumab) within 6 months of screening
* Therapeutic Plasma Exchange within 28 days of screening
* Previous renal transplantation
* Co-morbidity, which in physicians' view, would preclude patient from treatment with immunoadsorption.
* Pregnant at time of screening

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes